Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer.
about
Pterostilbene-isothiocyanate conjugate suppresses growth of prostate cancer cells irrespective of androgen receptor statusAndrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer.Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cellsIntracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.Screening of natural compounds as activators of the keap1-nrf2 pathway.Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancerInhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81).Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors.Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.Diterpenes and Their Derivatives as Potential Anticancer Agents.Genetic polymorphisms in the androgen metabolism pathway and risk of prostate cancer in low incidence Malaysian ethnic groups.Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.Andrographolide Induces Cell Cycle Arrest and Apoptosis of Chondrosarcoma by Targeting TCF-1/SOX9 Axis.Recent discoveries and developments of androgen receptor based therapy for prostate cancerDual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain
P2860
Q28541923-12467B85-1D91-41FA-B2B4-0001CAC57D31Q34053857-FE18A974-DDC6-4DFB-8773-0287F1C687C5Q34389853-6EFD2569-2201-4BB4-8CDF-5867D34F376FQ34461177-71824197-FFA7-4040-A687-CD7437BDBDA4Q35059810-8D70F147-7A33-45C8-986E-597FA7E1C5ABQ35150756-9D4DA2D9-7A53-45CE-B290-C35408C7CED7Q36248478-5A37B8A5-AD83-4714-BAC7-44B10C1C6350Q36838437-3F77B7C7-70FA-4855-B771-FBC5ED52D552Q38735379-22D33341-9F14-41C9-9379-088901C60DF1Q38875469-5EC7584D-C9BF-48B4-8A75-5414A3AE5489Q39216218-50DE0EA7-8AA0-4CD0-B046-537335BF3984Q41564601-C85E3000-C8C5-4B1B-996F-2B3CC68F0129Q46095028-72FAEDD6-E5E0-4819-AB5A-975BCF4F419DQ48171341-621D4385-ED56-4155-8B0B-DD45B5D4A9CCQ56621622-E30BD41E-776E-4ABF-A499-D74483D4539CQ58611891-D8E1A1BF-64EB-4B05-B31F-EC0C735E6EB1
P2860
Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Andrographolide targets androg ...... ion-resistant prostate cancer.
@ast
Andrographolide targets androg ...... ion-resistant prostate cancer.
@en
type
label
Andrographolide targets androg ...... ion-resistant prostate cancer.
@ast
Andrographolide targets androg ...... ion-resistant prostate cancer.
@en
prefLabel
Andrographolide targets androg ...... ion-resistant prostate cancer.
@ast
Andrographolide targets androg ...... ion-resistant prostate cancer.
@en
P2093
P2860
P356
P1433
P1476
Andrographolide targets androg ...... ion-resistant prostate cancer.
@en
P2093
Allen C Gao
Chengfei Liu
Christopher P Evans
Jae Yeon Chun
Nagalakshmi Nadiminty
Qinghua Zhou
Ramakumar Tummala
P2860
P304
P356
10.1177/1947601911409744
P577
2011-02-01T00:00:00Z